Product Presentation

Pharmalink dominates the natural anti-inflammatory compounds

Format: Webpage | Document type: Product Presentation | Promoted Content

This content is provided by Pharmalink International Ltd, and any views and opinions expressed do not necessarily reflect those of

Pharmalink dominates the natural anti-inflammatory compounds

Pharmalink International Ltd, owner of the patents for the anti-inflammatory oil of the New Zealand green-shell mussel, continues to introduce new anti-inflammatory compounds. It has been reported in the August edition of the Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology Journal how the Pharmalink compounds modulate inflammation via the COX and LOX pathways. The products offered by Pharmalink and used in 23 countries include the following three compounds: MO-CO2SFE95 compound: Pharmalink's patented mussel oil produced by CO2 supercritical fluid extraction from the New Zealand green-shell mussel (Perna canaliculus). This is the ultimate compound to include in anti-inflammatory formulations that require modulated responses to the LOX and COX pathways. This pure supercritical fraction of non-polar lipids is regarded as the world's most powerful anti-inflammatory for the treatment of chronic conditions. Available for formulation. MO-AML0607 compound: Pharmalink's patent pending mussel oil produced with the help of food enzymes to improve the extraction of all the active marine lipids. This new product for formulators provides a full spectrum of polar and non-polar lipids. This product is being supplied to formulators for the first time. Please contact us if you want to launch products during 2008. We have identified in MO-AML0607, a unique group of free fatty acids that have evolved as the most potent group of omega-3 lipids that modulate the 5-lipoxygenase metabolic pathway responsible for inflammation in the body. Available for formulation. Lyprinol®: Pharmalink's trademarked retail brand backed by human clinical trials that confirm positive results for more than 70 per cent of cases related to arthritis and asthma. More importantly, Lyprinol® has been found to be safe in clinical tests. It is the leading natural alternative to the synthetic COX Inhibitors, which continue to raise major health and recall concerns across the world. Lyprinol® has been used successfully by sufferers of inflammatory diseases such as arthritis and asthma for more than 10 years. Technical information: HOW DOES IT WORK? Ask us for additional information about how it works. We will gladly send you detailed product information. Pharmalink's active lipid fractions have been used successfully for the treatment of osteoarthritis, rheumatoid arthritis and asthma and are being studied for effectiveness against other inflammatory disorders such as Crohn's disease, ulcerative colitis, lupus, psoriasis and others. Our compounds are natural food extracts, which do not cause gastrointestinal toxicity, nor do they have any known side effects. Importantly, this compound does not thin the blood. It has a proven high potency. A series of studies have compared Lyprinol® with other health food products that are claimed to have anti-arthritic properties. For example, when using the adjuvant poly arthritis test system, on a dosage per body weight basis, Lyprinol® is a superior alternative for controlling the joint swelling that is associated with arthritis.

Related resources from Pharmalink International Ltd

Supplier info centre